首页 > 市场调查报告书 > 製药

感染疾病

甲癣治疗市场规模、份额及成长分析（按类型、通路、治疗方法和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1897253

甲癣治疗市场规模、份额及成长分析（按类型、通路、治疗方法和地区划分）－2026-2033年产业预测

Onychomycosis Treatment Market Size, Share, and Growth Analysis, By Type (Distal Subungual Onychomycosis, Candida Onychomycosis), By Distribution Channel, By Treatment Type, By Region-Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 208 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，甲癣治疗市场规模将达到 53.3 亿美元，到 2025 年将达到 57.9 亿美元，到 2033 年将达到 112 亿美元，预测期（2026-2033 年）的复合年增长率为 8.6%。

灰指甲治疗市场专注于采用各种治疗方法治疗真菌性感染疾病，包括外用药物、雷射治疗和口服抗真菌药物。灰指甲病例的增加、治疗方法选择的增加以及公众意识的提高是推动市场成长的关键因素。此外，医疗保健支出的成长也使得更多患者能够获得先进的治疗方法。然而，高昂的治疗费用和潜在的副作用对市场成长构成挑战。许多先进的治疗方法，例如雷射治疗和口服药物，价格昂贵且可能有风险，例如肝损伤和胃肠道不适，这导致患者不愿接受治疗。儘管如此，药物研发领域的创新，例如基于奈米技术的药物递送系统、缓释性和有效的外用疗法的进步，预计将推动市场成长。

甲癣治疗的驱动因素

人口老化、糖尿病盛行率上升以及免疫功能低下患者数量的增加正在推动灰指甲治疗市场的成长。此外，患者对该疾病的认识不断提高，加上诊断能力的提升以及医疗专业人员对先进治疗方法的了解不断加深，导致确诊病例数量激增。随着患者和医疗服务提供者都在寻求更好的方法来应对这种常见疾病，人们对甲癣的认识和了解不断加深，对有效治疗方法的需求也显着增长。因此，这些相互关联的因素正在推动市场显着成长。

甲癣治疗市场的限制因素

目前可用于治疗灰指甲的各种疗法可能并非对所有患者都完全有效，并且可能增加症状復发的风险。这些疗法的疗效可能因真菌感染疾病的特定类型和严重程度而异，这凸显了该领域持续研究和开发的重要性。由于患者对治疗的反应各不相同，因此人们越来越需要能够满足甲癣患者多样化需求的创新解决方案。克服这些限制对于推进治疗方案的开发和改善患者预后至关重要。

甲癣治疗市场趋势

先进雷射疗法的引入，特别是二氧化碳 (CO2) 雷射和蓝光雷射，已成为甲癣治疗市场的一大趋势。 CO2 雷射因其能够深入甲组织，有效靶向顽固真菌感染疾病而广受欢迎。这项技术是对传统治疗方法的补充，并因其精准性和有效性而备受青睐。同时，蓝光雷射已成为治疗轻度感染疾病或与其他治疗方法合併辅助性治疗的可行选择。这项利用热能对抗真菌的技术，反映了灰指甲治疗领域对微创高效解决方案日益增长的需求。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Teva Pharmaceutical Industries Ltd.（Israel）
Sanofi SA（France）
Medimetriks Pharmaceuticals, Inc.（US）
Galderma（Switzerland）
Johnson & Johnson（US）
Novartis AG（Switzerland）
Moberg Pharma AB（Sweden）
Cardinal Health, Inc.（US）
Pfizer Inc.（US）
Almirall, SA（Spain）
Bayer AG（Germany）
Viatris Inc.（US）
GlaxoSmithKline plc（UK）
Cipla Ltd.（India）
Dr. Reddy's Laboratories Ltd.（India）
Evofem Biosciences, Inc.（US）
Nabriva Therapeutics plc（Ireland）
Kaken Pharmaceutical Co., Ltd.（Japan）
Hikma Pharmaceuticals PLC（UK）
Dermavant Sciences, Inc.（US）
Sientra, Inc.（US）
Zynerba Pharmaceuticals, Inc.（US）

简介目录

Product Code: SQMIG35H2265

Onychomycosis Treatment Market size was valued at USD 5.33 Billion in 2024 and is poised to grow from USD 5.79 Billion in 2025 to USD 11.2 Billion by 2033, growing at a CAGR of 8.6% during the forecast period (2026-2033).

The onychomycosis treatment market focuses on addressing nail fungal infections through various modalities, including topical solutions, laser therapies, and oral antifungal medications. A rise in onychomycosis cases, enhanced treatment options, and increased awareness are key drivers of market expansion. Additionally, rising healthcare expenditures enable broader access to advanced therapies. However, high treatment costs and potential side effects present challenges to market growth, as many advanced options, such as laser therapies and oral medications, can be prohibitively expensive and may pose risks like liver damage or gastrointestinal issues, causing patient reluctance. Nonetheless, the market is poised for growth through innovations in drug development, including advancements in drug delivery systems utilizing nanotechnology, sustained-release formulations, and effective topical treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Onychomycosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Onychomycosis Treatment Market Segments Analysis

Global Onychomycosis Treatment Market is segmented by Treatment Type, Disease Indication, Age Group, Gender, Distribution Channel, and region. Based on Treatment Type, the market is segmented into Drugs, Lasers, and Photodynamic Therapy. Based on Disease Indication, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candidal Onychomycosis, and Total Dystrophic Onychomycosis. Based on Age Group, the market is segmented into 0 to 18 Years, 19 to 39 Years, 40 to 64 Years, and 65 Years & Above. Based on Gender, the market is segmented into Male, and Female. Based on Distribution Channel, the market is segmented into Institutional Sales, and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Onychomycosis Treatment Market

The expanding incidence of fungal nail infections driven by an aging population, rising diabetes prevalence, and an increase in immune-compromising conditions is propelling the onychomycosis treatment market. Additionally, heightened awareness about the condition among patients, coupled with improved diagnostic capabilities and advanced treatment options recognized by healthcare professionals, is leading to a surge in diagnoses. This growing recognition and understanding of onychomycosis are significantly contributing to the demand for effective treatments, as both patients and providers seek better solutions for managing this prevalent condition. As a result, the market is witnessing substantial growth driven by these interrelated factors.

Restraints in the Onychomycosis Treatment Market

Currently, various treatments available for Onychomycosis may not provide adequate effectiveness for every patient, leading to a higher likelihood of recurrence of the condition. The efficacy of these treatments can vary based on the specific type and severity of the fungal infection, highlighting the importance of ongoing research and development in this area. As different patients respond uniquely to treatments, there is an increasing demand for innovative solutions that can cater to the diverse needs of those affected by Onychomycosis. Addressing these limitations is crucial for advancing treatment options and improving patient outcomes.

Market Trends of the Onychomycosis Treatment Market

The Onychomycosis Treatment market is witnessing a notable trend toward advanced laser therapies, particularly the adoption of Carbon Dioxide (CO2) and Blue Light lasers. CO2 lasers are gaining prominence due to their ability to deeply penetrate nail tissues, effectively targeting stubborn fungal infections. This technology is complementing traditional treatments and is preferred for its precision and efficacy. Meanwhile, Blue Light lasers are emerging as a viable option for milder infections or as an adjunct to other therapeutic modalities, harnessing heat energy to combat fungi. This shift towards innovative laser treatments reflects a growing demand for less invasive, effective solutions in the nail fungus treatment segment.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
PESTEL Analysis
Top Investment Analysis
Key Success Factor
Degree of Competition

Onychomycosis Treatment Market by Treatment Type

Market Overview
Drugs
- Oral
- RX
- OTC
- Tropical
- RX
- OTC
Lasers
- C02 Ablative Lasers
- Nd: YAG Lasers
- Dual-wavelength near-infrared Lasers
Photodynamic Therapy

Onychomycosis Treatment Market by Disease Indication

Market Overview
Distal Subungual Onychomycosis
White Superficial Onychomycosis
Proximal Subungual Onychomycosis
Candidal Onychomycosis
Total Dystrophic Onychomycosis

Onychomycosis Treatment Market by Age Group

Market Overview
0 to 18 Years
19 to 39 Years
40 to 64 Years
65 Years & Above

Onychomycosis Treatment Market by Gender

Market Overview
Male
Female

Onychomycosis Treatment Market by Distribution Channel

Market Overview
Institutional Sales
- Hospitals
- Dermatology Clinics
Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies & Online Sales

Onychomycosis Treatment Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medimetriks Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Galderma (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moberg Pharma AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cardinal Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almirall, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evofem Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nabriva Therapeutics plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kaken Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dermavant Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sientra, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zynerba Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments